News | April 26, 2010

European Trial Explores Potential of Renal Stent

April 21, 2010 — A landmark clinical trial has begun in Europe to explore the safety and efficacy of a paclitaxel-eluting stent for the treatment of renal artery disease.

Cook Medical, a license holder of Angiotech Pharmaceuticals Inc.’s stent technology, has enrolled the first patient in the Formula clinical trial. The multicenter, randomized trial plans to enroll 120 patients at sites across Europe. The trial utilizes Cook's Formula renal stent, which is designed with a very low profile that may help it cross tightly blocked vessels for placement into diseased renal arteries.

"Following Cook Medical's success with the Zilver PTX, we chose to be involved in the clinical trial for the Formula PTX balloon expandable renal stent," said Dierk Scheinert, professor and angiology and cardiology specialist at participating hospital, Park-Krankenhaus Leipzig-South. "Given the early success of the US REFORM clinical trial evaluating the Formula balloon expandable stent, we remain very excited about the potential of a drug-eluting renal stent."

"Providing physicians with a greater range of devices will ultimately help patients receive the best possible treatment options," Scheinert added.

Renal artery disease is a narrowing of the arteries that supply blood to the kidneys, increasing the risk of a stroke due to high blood pressure, and possible renal insufficiency and kidney failure.

For more information: www.angiotech.com, www.cookmedical.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
CDN to Integrate Advanced Cardiac Imaging Tools From DiA Imaging Analysis
Technology | August 10, 2017
August 10, 2017 — CDN recently announced a new partnership agreement with DiA Imaging Analysis Ltd., makers of next-g
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
3D printing of the heart and coronary artery tree from a patient's CT scan.
Sponsored Content | Webinar | 3-D Printing| August 09, 2017
Learn how 3-D printing empowers medical device manufacturer Medtronic to bring products to market faster, develop bet
Overlay Init